Targeting Phage Therapy

Complex Phage Communities Control Gut (im)balances and May Hold the Key to Restore Gut Biosis. Hot topic of Targeting Phage Therapy 2025 Dr. Dennis Sandris Nielsen from the University of Copenhagen (Københavns Universitet), Denmark, will give an oral presentation at the 8th World Congress Targeting Therapy. The title of his talk is Complex Phage Communities Control Gut (im)balances and May Hold the Key to Restore Gut Biosis. A few points of Dr. Nielsen's presentation: Phages play important roles in maintaining gut microbial biosis Imbalances in the gut phage population may lead to disease Gut microbial imbalances can be restored by the transfer of fecal viromes from healthy donors, alleviating (some) gut microbiome dysbiosis associated diseases. Other speakers of Session 2: Phage Therapy & Gut Microbiota • Franklin L. Nobrega (University of Southampton): KlebPhaCol: Novel Gut Phage Order Associated with the Human Gut • Domenico Frezza (University of Roma Tor Vergata): Optimizing the Phage-Bacteria Ratio in Phage Therapy: Metagenomic Insights into Microbial Balance and Dysbiosis We remind you that the Deadline for the Short Oral submission is May 2, and Early Bird Registration is April 22! For more information: https://lnkd.in/egH62bTR #PhageTherapy #Microbiology #AntimicrobialResistance #Microbiota #Phage

Speaker Spotlight: Prof. Mikael Skurnik at the 8th World Conference on Targeting Phage Therapy: Yersinia Phage Stories: Impact on Phage Therapy. We're pleased to announce that Professor Mikael Skurnik from the University of Helsinki, Finland will be presenting during Session 1 - Phage-Bacteria Interactions & Resistance at the upcoming 8th World Conference on Targeting Phage Therapy. His presentation, "Yersinia Phage Stories: Impact on Phage Therapy" will share valuable insights on bacteriophages targeting Yersinia and their implications for phage therapy applications. Other speakers with Prof. Mikael Skurnik: Christian Willy, Stan Brouns, Jumpei Fujiki For more information & registration: https://lnkd.in/egH62bTR #PhageTherapy #Microbiology #YersiniaPhages #ConferenceAnnouncement #BerlinConference

Speakers of Targeting Phage Therapy 2025 | June 10-11, Berlin, Germany. We are excited to share the speaker lineup for the 8th World Conference on Targeting Phage Therapy at DoubleTree by Hilton Berlin Kudamm! Keynote: Robert Schooley (UCSD) Session 1: Phage-Bacteria Interactions & Resistance • Christian Willy (Academic Hospital Bundeswehr Berlin) • Stan Brouns (Delft University of Technology) • Jumpei Fujiki (Rakuno Gakuen University) • Mikael Skurnik (University of Helsinki) Session 2: Phage Therapy & Gut Microbiota • Dennis Sandris Nielsen (University of Copenhagen (Københavns Universitet) • Franklin L. Nobrega (University of Southampton) • Domenico Frezza (University of Roma Tor Vergata) Session 3: Phage Therapy in Oncology • Alberto Danielli (University of Bologna (Alma Mater Studiorum – Università di Bologna)) • Alena Kaltenbrunner (University of Bologna) Session 4: Innovative Phage Applications • Loris Rizzello (University of Milan) • Marco Cafora (University of Milan) • Jeremy Barr (Monash University) • Christian Kühn (Hannover Medical School) • Gail L. Stanley (Yale University) Session 5: Veterinary & Agricultural Medicine • Hidetomo Iwano (Rakuno Gakuen University) • Sandra Sevilla Navarro (Centro de Calidad Avícola, Spain) Session 6: Regulatory & Ethical Landscape • Barbara Brenner (Kanzlei BRENNER, Germany) Special practical session on bringing phage products to market & round table on the future of phage therapy in Europe! We remind you that the Deadline for the Short Oral submission is May 2, and Early Bird Registration is April 22! For more information: https://lnkd.in/egH62bTR #PhageTherapy #Microbiology #AntimicrobialResistance #Microbiota #Phage

We are honored to welcome Prof. Christian Willy from Academic Hospital Bundeswehr Berlin at Targeting Phage Therapy 2025, which will take place on June 10th and 11th in Berlin and will discuss the revival of phage therapy as a crucial tool against antibiotic-resistant infections, particularly in military and civilian medical settings with a talk entitled Bacteriophage Therapy: A Renaissance – From Military Medicine to Civilian Healthcare Prof. Christian Willy will cover: - Historical Perspective & Modern Revival: Overview of bacteriophage use, from early 20th-century applications to its decline and resurgence in modern medicine. - Phage Therapy in Military Medicine: Insights from NATO and Bundeswehr-led initiatives on using phages for infected combat wounds, highlighting research from the PhagoFlow project. - Clinical Applications & Case Studies: Success stories and challenges of phage therapy in treating chronic, multidrug-resistant infections, including septic and reconstructive surgeries. - Future Directions & Integration with Modern Medicine Join us in Berlin for an insightful discussion on the future of phage therapy! 🔗 More about us: https://lnkd.in/egH62bTR #PhageTherapy #PhageTherapy2025 #TargetingPhageTherapy #InfectiousDiseases #MedicalInnovation #HealthcareFuture #Antibiotic #Phage

Endolysin B as a New Approach & Archetype in M. Tuberculosis Treatment. The future of Tuberculosis therapy will come through Phages? Tuberculosis (TB) remains a major global health challenge, with one person dying every 20 seconds—a crisis worsened by multi- and extensively drug-resistant (MDR/XDR) strains. Antibiotic misuse and the adaptability of Mycobacterium tuberculosis are making traditional treatments increasingly ineffective. Our latest research explores an alternative solution: Endolysin B (LysB), an enzyme produced by bacteriophages that targets and disrupts the mycobacterial cell wall. By engineering a fluorescent version of Ms6 LysB, we analyzed its binding to both non-pathogenic Mycobacterium smegmatis and the slow-growing pathogenic M. tuberculosis. The findings confirm that LysB binding can impair TB bacterial growth, offering a potential new therapeutic strategy. This work provides proof-of-principle that LysB could be an effective tool against TB, addressing the urgent need for innovative, resistance-proof treatments. More research is needed, but phage-derived enzymes like LysB may be the future of TB therapy. Prof. Loris Rizzello, from the Università degli Studi di Milano, Italy, will talk at the 8th World Congress Targeting Therapy this June in Berlin. 🔬 Read more: https://lnkd.in/emYCrKRA #Tuberculosis #AntibioticResistance #Bacteriophages #Endolysin #BiotechInnovation #PhageTherapy #infectiousdiseases

🔊 Keynote Speech: Prof. Robert T. Schooley at Targeting Phage Therapy 2025! We are honored to welcome Pr. Robert Schooley from UC San Diego School of Medicine as a keynote speaker at Targeting Phage Therapy 2025, which will take place on June 10th and 11th in Berlin. 🎤 Talk Title : "Phage Therapy 2030: Getting from Here to There" With the rapid acceleration of phage therapy in clinical medicine over the past decade, its impact is expected to grow even further by 2030. In his keynote, Prof. Schooley will explore where phage therapy is headed and what it will take to reach its full potential. About Prof. Robert T. Schooley: 📌 Leading expert in infectious diseases, HIV, and hepatitis C 📌 Professor at UC San Diego School of Medicine 📌 Pioneer in immune responses to HIV & global health initiatives 📌 Author of hundreds of research articles & books Join us in Berlin for an insightful discussion on the future of phage therapy! 🔗 More about us : https://lnkd.in/egH62bTR #PhageTherapy #PhageTherapy2025 #TargetingPhageTherapy #InfectiousDiseases #MedicalInnovation #HealthcareFuture #HIV #HepatiteC #Phage

Bacteriophage Therapy in Pediatrics: A Potential Solution to Multidrug-Resistant Infections! Bacteriophage therapy, which targets specific bacterial pathogens, is gaining attention as a potential alternative to antibiotics, especially for multidrug-resistant infections in children. Recent discussions, including insights from John S. Bradley at the UC San Diego, highlight the promise of phage therapy for both acute and chronic pediatric infections. The therapy's ability to target only harmful bacteria while preserving the microbiome could offer a more precise treatment option, particularly when combined with traditional antibiotics. 🔗 : https://lnkd.in/dwXqTCZa #BacteriophageTherapy #PediatricInfections #AntibioticResistance #PhageTherapy #MultidrugResistance #TargetedTreatment #PrecisionMedicine #ChildHealth #AntibioticsAlternative #HealthcareInnovation #Microbiome #InfectiousDiseases

Can phage therapy help combat antibiotic-resistant infections? Phage therapy is a promising tool in the fight against multidrug-resistant infections. In a recent review, Teiji Sawa and his team at Kyoto Prefectural University of Medicine highlighted clinical cases showing the potential of phage therapy, particularly for treating infections caused by Pseudomonas aeruginosa and Acinetobacter. Ongoing research is focused on refining phage selection, combination strategies, and clinical applications to enhance treatment efficacy. With initiatives like Belgium's national phage bank and the IPATH program at UC San Diego, phage therapy is moving toward becoming a valuable part of personalized medicine in addressing antibiotic resistance. 🔗 : https://lnkd.in/dt8mMXvK #PhageTherapy #AntibioticResistance #Bacteriophages #InfectiousDiseases

How do bacteriophages shape the gut microbiome and influence Klebsiella colonization? A recent study led by Franklin L. Nobrega (University of Southampton) introduces KlebPhaCol, an open-source resource featuring 53 fully characterized phages and 74 Klebsiella isolates, including a newly identified gut-associated phage order, Felixvirales. With Klebsiella’s rising antibiotic resistance, KlebPhaCol provides a crucial platform for understanding phage-bacteria interactions and advancing therapeutic strategies. 🔗 : https://lnkd.in/dCPznWU7 ❓ Want to learn more? Dr. Franklin L. Nobrega will present this research at Targeting Phage Therapy 2025, June 10-11 in Berlin. Stay tuned for insights into the future of phage-based strategies! Conference Details: https://lnkd.in/egH62bTR #TargetingPahgeTherapy #PhageTherapy #GutMicrobiome #Klebsiella #Bacteriophages #AntimicrobialResistance #MicrobiomeResearch #InfectiousDiseases #Felixvirales #PrecisionMedicine